Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
Author:
Publisher
Elsevier BV
Subject
General Medicine
Reference7 articles.
1. Primary medical therapy for acromegaly;Sheppard;Clin Endocrinol (Oxf),2003
2. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant;Trainer;N Engl J Med,2000
3. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist;van der Lely;Lancet,2001
4. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient;van der Lely;J Clin Endocrinol Metab,2001
5. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly;Jehle;J Clin Endocrinol Metab,2005
Cited by 199 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE);Pituitary;2024-06-04
2. Standards of Care for Medical Management of Acromegaly in Pituitary Tumor Centers of Excellence (PTCOE);2024-03-18
3. Efficacy and Safety of Pegvisomant in the Treatment of Acromegaly;Archives of Medical Research;2023-12
4. Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience;Journal of Endocrinological Investigation;2023-03-09
5. Second line treatment of acromegaly: Pasireotide or Pegvisomant?;Best Practice & Research Clinical Endocrinology & Metabolism;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3